What is William Blair’s Estimate for VIGL Q1 Earnings?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Vigil Neuroscience in a research report issued on Thursday, March 13th. William Blair analyst S. Schram expects that the company will post earnings per share of $0.49 for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. William Blair also issued estimates for Vigil Neuroscience’s Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.12) EPS.

Several other equities analysts have also recently weighed in on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. HC Wainwright dropped their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, March 14th. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Finally, Wedbush dropped their target price on shares of Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, March 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Stock Performance

Shares of NASDAQ VIGL opened at $1.97 on Monday. Vigil Neuroscience has a fifty-two week low of $1.49 and a fifty-two week high of $6.06. The stock has a market cap of $80.53 million, a price-to-earnings ratio of -0.96 and a beta of 1.82. The firm’s 50-day simple moving average is $2.34 and its 200 day simple moving average is $2.76.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08).

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VIGL. Woodline Partners LP grew its position in shares of Vigil Neuroscience by 239.1% during the 4th quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock valued at $831,000 after purchasing an additional 344,614 shares in the last quarter. Blair William & Co. IL purchased a new position in shares of Vigil Neuroscience during the 4th quarter valued at $551,000. Renaissance Technologies LLC grew its position in shares of Vigil Neuroscience by 698.5% during the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company’s stock valued at $624,000 after purchasing an additional 321,300 shares in the last quarter. abrdn plc grew its position in shares of Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after purchasing an additional 293,461 shares in the last quarter. Finally, Trustees of Columbia University in the City of New York purchased a new position in Vigil Neuroscience in the fourth quarter worth $328,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.